Advantages of NMNH
NMNH: 1. “Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues manufacturing powder. 2. Bontac is a very first manufacture in the world to produce the NMNH powder on the level of high purity, stability. 3. Exclusive “Bonpure” seven-step purification technology, high purity（up to 99%) and stability of production of NMNH powder 4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products of NMNH powder 5. Provide one-stop product solution customization service
Advantages of NADH
NADH: 1. Bonzyme whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Exclusive Bonpure seven-step purification technology, purity up higher than 98 % 3. Special patented process crystal form, higher stability 4. Obtained a number of international certifications to ensure high quality 5. 8 domestic and foreign NADH patents, leading the industry 6. Provide one-stop product solution customization service
Advantages of NAD
NAD: 1. “Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Stable supplier of 1000+ enterprises around the world 3. Unique “Bonpure” seven-step purification technology, higher product content and higher conversion rate 4. Freeze drying technology to ensure stable product quality 5. Unique crystal technology, higher product solubility 6. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products
Advantages of MNM
NMN: 1. “Bonzyme”Whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Exclusive“Bonpure”seven-step purification technology, high purity（up to 99.9%) and stability 3. Industrial leading technology: 15 domestic and international NMN patents 4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products 5. Multiple in vivo studies show that Bontac NMN is safe and effective 6. Provide one-stop product solution customization service 7. NMN raw material supplier of famous David Sinclair team of Harvard University
We Have The Best Solutions for Your Business
Bontac Bio-Engineering (Shenzhen) Co., Ltd. (hereafter referred to as BONTAC) is a high-tech enterprise established in July 2012. BONTAC integrates R&D, production and sales, with enzyme catalysis technology as the core and coenzyme and natural products as main products. There are six major series of products in BONTAC, involving coenzymes, natural products, sugar substitutes, cosmetics, dietary supplements and medical intermediates.
As the leader of the global NMN industry, BONTAC has the first whole-enzyme catalysis technology in China. Our coenzyme products are widely used in health industry, medical & beauty, green agriculture, biomedicine and other fields. BONTAC adheres to independent innovation, with more than 170 invention patents. Different from the traditional chemical synthesis and fermentation industry, BONTAC has advantages of green low-carbon and high-value-added biosynthesis technology. What’s more, BONTAC has established the first coenzyme engineering technology research center at the provincial level in China which also is the sole in Guangdong Province.
In the future, BONTAC will focus on its advantages of green, low-carbon and high-value-added biosynthesis technology, and build ecological relationship with academia as well as upstream/downstream partners, continuously leading the synthetic biological industry and creating a better life for human beings.
NMN powder manufacturing method
NMN powder in general is typically produced via chemical or enzymatic synthesis, or fermentation biosynthesis. There are pros and cons to all three methods.
Chemical synthesis is expensive and labor intensive, and all raw ingredients used are categorized as “unnatural,” i.e., not from biological systems. There are, however, some advantages from the manufacturer’s perspective. The yield is well suited to mass NMN powder production, and all of those unnatural raw ingredients can be carefully controlled. But there are a number of drawbacks as well. Some of the solvents used in the manufacturing process are seriously bad from an environmental standpoint, and impurities and by-products can be challenging to remove from the finished product – that’s seriously bad for the consumer.
Enzymatic production of NMN powder, on the other hand, is considered a “green preparation method.” Like the chemical route, it’s pricey, but it offers a higher yield and impressively high purity. The finished NMN ticks all the boxes – stable, easily absorbed, lightweight, low density, and a low molecular structure.
Fermentation has also been explored as a method of producing NMN, but yield, though high quality, is pretty abysmal, so many supplement companies quite sensibly look to other, more efficacious processes.
NMN powder efficacy in health
NMN was only considered as a source of cellular energy and an intermediate in NAD+ biosynthesis, currently, the attention of the scientific community has been paid on anti-aging activity and a variety of health benefits and pharmacological activities of NMN which are related to the restoring of NAD+. Thus, NMN has therapeutic effects towards a range of diseases, including age-induced type 2 diabetes, obesity, cerebral and cardiac ischemia, heart failure and cardiomyopathies, Alzheimer’s disease and other neurodegenerative disorders, corneal injury, macular degeneration and retinal degeneration, acute kidney injury and alcoholic liver disease.
BONTAC NMN product features and advantages
1、“Bonzyme”Whole-enzymatic method, environmental-friendly, no harmful solvent residues manufacturing powder
2、Exclusive“Bonpure”seven-step purification technology, high purity（up to 99.9%) and stability of production of NMN powder
3、Industrial leading technology: 15 domestic and international NMN patents
4、Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products of NMN powder
5、Multiple in vivo studies show that Bontac NMN powder is safe and effective
6、Provide one-stop product solution customization service
7、NMN raw material supplier of famous David Sinclair team of Harvard University.
User Reviews
What users say about BONTAC
Frequently Asked Question
Do you have any question?
Aging, as a natural process is identified by downregulation of energy production in mitochondria of various organs such as brain, adipose tissue, skin, liver, skeletal muscle and pancreas due to the depletion of NAD+ . NAD+ levels in the body decrease as a consequence of increasing NAD+ consuming enzymes when aging There are three different biosynthesis pathways to produce NAD+ in mammalian cells including de novo synthesis from tryptophan, salt and Preiss-Handler pathways. Among these three pathways, NMN is an interproduct by is involved in NAD+ biosynthesis through salt and Preiss-Handler pathways. The salvage pathway is the most efficient and the main route for the NAD+ biosynthesis, in which nicotinamide and 5-phosphoribosyl-1-pyrophosphate are converted to NMN with the enzyme of NAMPT followed by conjugation to ATP and conversion to NAD by NMNAT. Furthermore, NAD+ consuming enzymes are responsible for degradation of NAD+ and consequence nt formation of nicotinamide as a by-product.
The safety of NMN powder cannot be assessed since required clinical and toxicological studies have not been completed yet to establish the recommended safe levels for long term administration. Nevertheless, their safety and efficacy are uncertain and unreliable since most of them have not been back by Rigorous scientific preclinical and clinical testing. This issue has been arisen as manufacturers are hesitant to pay for research and clinical trials due to potential lower profit margin, and there is no authorizing agency to regulate NMN products because it is often product sold as functional food than heavily regulated therapeutic drug. Therefore, more strict approval process has been demanded by consumer advocacy groups requesting regulatory agencies to set standard and restrictions for marketing anti-aging health products, considering safety, health and wellbeing of N red besumers. a panacea for the elderly, because boosting NAD levels when not required may yield some detrimental effects. Therefore, the dose and frequency of NMN supplementation should be carefully prescribed depending on the type of age-related deficiency and all other confronting health conditions of the people. Other NAD precursors over have been studied to diverse age-related deficiencies and they are used for particular deficiencies, only after they are proven for effectiveness and safe to use. Therefore, the same principle should be applied to NMN as well
First, inspect the factory. After some screening, NMN companied that directly face consumers pay more attention to brand building. Therefore, for a good brand, quality is the most important thing, and the first thing to control the quality of raw materials is to inspect the factory. Bontac company actually manufacturing NMN powder of high quality with the caterias of SGS. Secondly, the purity is tested. Purity is one of the most important parameters of NMN powder. If high purity NMN cannot be guaranteed, the remaining substances are likely to exceed the relevant standards. As the attached certificates demonstrates that the NMN powder produced by Bontac reach the purity of 99.9%. Finally, a professional test spectrum is needed to prove it. Magnetic Resonance Spectroscopy (NMR) and high-resolution mass spectrometry (HRMS). Usually through the analysis of these two spectra, the structure of the compound ca n be preliminarily determined.
Our updates and blog posts
Maternal NAD Precursor Supplementation to Reduce the Risk of Developing CNDD
1. Introduction Nicotinamide adenine dinucleotide (NAD) has been unveiled to be essential for embryonic development. Patients with genetic variants in the NAD+ de novo synthesis pathway often have congenital NAD deficiency disorder (CNDD), a multisystem condition inherited in an autosomal recessive manner. In the context of NAD+ deficiency, all organs and systems, not just vertebrae, heart, kidneys, and limbs, may be affected. 2. The association between NAD synthetase 1 (NADSYN1) and CNDD Individuals delivering biallelic NADSYN1 variants share similar clinical features to those with CNDD. Up till now, almost all of the identified CNDD cases can be attributed to biallelic loss-of-function variants in any of 3 nonredundant genes of the NAD de novo synthesis pathway, including kynureninase (KYNU), 3-hydroxyanthranilate 3,4-dioxygenase (HAAO), or NADSYN1. Among individuals with CNDD identified to date, those with biallelic pathogenic NADSYN1 variants are the most diverse in phenotype. 3. The impact of NADSYN1 variants upon enzymatic activity and phenotype Specifically, NADSYN1 can catalyse the amidation of nicotinic acid adenine dinucleotide (NaAD) to NAD. Biallelic pathogenic variants in NADSYN1 cause a metabolic block in both the de novo pathway and the Preiss-Handler pathway, leading to NAD deficiency. Biallelic NADSYN1 loss-of-function variants impact the NAD metabolome of humans. Post-birth phenotypes involve feeding difficulties, developmental delay, short stature, etc. 4. Mouse embryogenesis disrupted by the loss of NADSYN1 In NADSYN1-/- mouse embryos, NAD-dependent malformations occur when maternal dietary NAD precursors are limited during gestation. The affected Nadsyn1-/- embryos most frequently present malformations of the kidneys, eyes, and lungs. 5. The preventative effect of amidated NAD precursor supplementation against CNDD NADSYN1-dependent embryo loss and malformation in mice are preventable by dietary supplementation of amidated NAD precursors (NMN and NAM) during pregnancy. Maternal diet–derived NAD precursors primarily determine the development of healthy embryos. 6. Conclusion NAD-boosting supplements are essential for individuals with biallelic loss-of-function variants in NADSYN1. Maternal NAD precursor supplementation, to some extent, can reduce the risk of developing CNDD. Reference Szot JO, Cuny H, Martin EM, et al. A metabolic signature for NADSYN1-dependent congenital NAD deficiency disorder. J Clin Invest. 2024;134(4):e174824. Published 2024 Feb 15. doi:10.1172/JCI174824 About BONTAC BONTAC has been dedicated to the R&D, manufacture and sale of raw materials for coenzyme and natural products since 2012, with self-owned factories, over 170 global patents as well as strong R&D team consisting of Doctors and Masters. BONTAC has rich R&D experience and advanced technology in the biosynthesis of NAD and its precursors (eg. NMN and NR), with various forms to be selected (eg. endoxin-free IVD-grade NAD, Na-free or Na-containing NAD; NR-CL or NR-Malate). High quality and stable supply of products can be better ensured here with the exclusive Bonpure seven-step purification technology and Bonzyme Whole-enzymatic method. Disclaimer This article is based on the reference in the academic journal. The relevant information is provide for sharing and learning purposes only, and does not represent any medical advice purposes. If there is any infringement, please contact the author for deletion. The views expressed in this article do not represent the position of BONTAC. Under no circumstances will BONTAC be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your reliance on the information and material on this website.
Transcriptome and Metabolome Profiling on the Potential of NMN/NR Against NAFLD
Introduction Disturbance in hepatic NAD+ metabolism has been manifested as a key factor in the initiation and progression of nonalcoholic fatty liver disease (NAFLD), one of the most common chronic liver disease worldwide. Therapeutic methods aiming to increase NAD+ level are promising for NAFLD treatment. Both NMN and NR can raise NAD+ level. This research is designed to decipher their impacts and underpinned mechanism upon NAFLD based on the transcriptome and metabolome profiling. NMN vs. NR Relative to NR, NMN has an added phosphate group. This added phosphate group makes NMN a larger molecule than NR. Even so, NMN can be transported into cells through specific transporters, such as Slc12a8. NR is intermediate product in the synthesis of NAD+, and NMN is the direct precursor of NAD+. Once inside cells, NMN can be converted to NAD+ under the catalysis of NMNATs, whereas NR needs to be first converted to NMN by NRKs before conversion to NAD+. The efficacy of NMN and NR in alleviating NAFLD In mice with high-fat diet (HFD)-induced NAFLD, NMN or NR is administered through daily oral gavage. It has been found that NMN and NR reduce body weight gain, improve glucose homeostasis, regulate plasma lipid levels, and ameliorate liver injury, oxidative stress and lipid accumulation in mice subjected to HFD feeding. Importantly, both NMN and NR alleviate the HFD-induced NAFLD in mice, as evidenced by the ameliorative hepatic steatosis, inflammation, and fibrosis. The mechanism underlying NAD+ precursor-mediated NAFLD remission Integrated transcriptome and metabolome analysis indicate that arachidonic acid metabolism and linoleic acid metabolism pathway are involved in NMN/NR-induced NAFLD amelioration. Specifically, NMN and NR reduce the saturated fatty acid (palmitic acid, stearate, and arachidic acid) content to protect mice from liver toxicity, alter the arachidonic acid metabolism to regulate immune and inflammatory responses, and restore the decreased polyunsaturated fatty acid (linoleic acid and eicosapentaenoic acid) content in the liver of NAFLD mice. Notably, Mup gene cluster, which can regulate lipid and energy metabolism, may function as a potential target for NMN and NR in the treatment of hepatic lipid accumulation. Furthermore, the CYP450 enzymes might be involved in NMN/NR-mediated arachidonic acid metabolism regulation. Conclusion Both NMN and NR administration significantly modify the hepatic lipid composition via Mup gene cluster, and alter linoleic acid metabolism and arachidonic acid metabolism pathways via CYP450 enzymes, which might mediate NAD+ administration-induced NAFLD remission. Reference Zhang J, Chen F. Integrated transcriptome and metabolome study reveal the therapeutic effects of nicotinamide riboside and nicotinamide mononucleotide on nonalcoholic fatty liver disease. Biomed Pharmacother. Published online May 9, 2024. doi:10.1016/j.biopha.2024.116701 BONTAC NMN and NR BONTAC has been dedicated to the R&D, manufacture and sale of raw materials for coenzyme and natural products since 2012, with self-owned factories, over 170 global patents as well as strong R&D team. BONTAC has rich R&D experience and advanced technology in the biosynthesis of NMN and NR. BONTAC is the pioneer of NMN industry and the first manufacturer to launch NMN mass production, with the first whole-enzyme catalysis technology around the world. BONTAC NMN is patent-grade and has obtained the self-affirmed GRAS certification of FDA. Strikingly, both malate and chloride salt forms of NR are available here. By dirt of unique Bonpure seven-step purification technology and Bonzyme Whole-enzymatic method, the product content and conversion rate can be maintained in a higher level. At present, BONTAC has become the leading enterprise in niche areas of coenzyme. The coenzyme products of BONTAC are widely used in fields such as nutritional health, biomedicine, medical beauty, daily chemicals and green agriculture. Disclaimer This article is based on the reference in the academic journal. The relevant information is provided for sharing and learning purposes only, and does not represent any medical advice purposes. If there is any infringement, please contact the author for deletion. The views expressed in this article do not represent the position of BONTAC. Under no circumstances will BONTAC be responsible in any way for any claims, damages, losses, expenses or costs arising directly or indirectly from your reliance on the information and material on this website.
A Key Role for NMN in Alleviating Organelle Miscommunication in HFD Mouse Liver
Introduction Recent research unveils that hepatic insulin resistance (IR) and steatosis in obesity have a strong association with endoplasmic reticulum (ER)-mitochondria miscommunication. Notably, β-nicotinamide mononucleotide (NMN) can ameliorate hepatic IR and steatosis to regulate obesity via reinforcing the interaction between ER and mitochondria. About ER-mitochondria miscommunication ER and mitochondria interact at contact sites called mitochondria-associated membranes (MAMs), where they exchange phospholipids and calcium (Ca2+). MAM acts as a bridge between the ER and mitochondria, participating in the regulation of calcium signaling, lipid homeostasis, mitochondrial dynamics, mitochondrial autophagy, and ER stress response. Disrupting ER-mitochondria communication may induce hepatic IR and steatosis. Research protocol In vivo, thirty 8-week-old male C57BL/6 J specific pathogen-free mice are fed with normal/high-fat diet (HFD) and normal/NMN-containing drinking water for 30 weeks. During the experiments, the body weight, diet, food intake, appearance, and behavior characteristics of the experimental mice are recorded weekly. A week prior to the end of study, 12-h-fasting mice are subjected with intraperitoneal injection of glucose (2 mg/g body weight) or insulin (0.75 mU/g body weight) for glucose tolerance test and insulin tolerance test, followed by the measurement of glycemia using a glucometer. In vitro, mouse normal hepatocytes NCTC1469 are seeded in 96-well microtiter plates for 12-h culture, then blended with specific palmitic acid (PA) for 36 h to establish the HFD model, and treated with NMN (500, 50, 5, 0.5, and 0.05 μM) for 24 h, followed by detection of physiological indicators. Regulatory impacts of NMN upon obesity In vivo, NMN ameliorates hyperlipidemia, hepatic steatosis, liver physiological metabolic damage, liver lipid metabolic abnormalities, and ER-mitochondrial miscommunication in the liver of HFD mice. In vitro, NMN reduces PA-induced lipid accumulation, yet promotes PA-induced mitochondrial-ER communication in NCTC1469 cells. NMN alleviates organelle miscommunication by increasing MAMs in HFD mice liver. Concretely, NMN ameliorates mitochondrial dysfunction and ER oxidative stress in the liver of HFD mice by increasing hepatic nicotinamide adenine dinucleotide (NAD+) level. This effect increases the MAMs between ER and mitochondria, thereby promoting intracellular ATP production and mitigating lipid metabolic disturbances in the liver of HFD mice. Conclusion NMN enhances the dynamic properties of MAMs to increase the communication between mitochondria and ER, ultimately reversing HFD-induced glycolipid metabolic disorder, IR and hepatic steatosis. Reference [1] Beaulant A, Dia M, Pillot B, et al. Endoplasmic reticulum-mitochondria miscommunication is an early and causal trigger of hepatic insulin resistance and steatosis. J Hepatol. 2022;77(3):710-722. DOI:10.1016/j.jhep.2022.03.017 [2] Lam BCC, Lim AYL, Chan SL, et al. The impact of obesity: a narrative review. Singapore Med J. 2023;64(3):163-171. DOI: 10.4103/singaporemedj.SMJ-2022-232 [3] Li Y, Tian X, Yu Q, et al. Alleviation of hepatic insulin resistance and steatosis with NMN via improving endoplasmic reticulum-mitochondria miscommunication in the liver of HFD mice. Biomed Pharmacother. Published online May 3, 2024. DOI:10.1016/j.biopha.2024.116682 BONTAC NMN BONTAC is the pioneer of NMN industry and the first manufacturer to launch NMN mass production, with the first whole-enzyme catalysis technology around the world. BONTAC NMN is patent-grade and has obtained the self-affirmed GRAS certification of FDA. At present, BONTAC has become the leading enterprise in niche areas of coenzyme. Our services and products have been highly recognized by global partners. Furthermore, BONTAC has the first national and the only provincial independent coenzyme engineering technology research center in Guangdong, China. The coenzyme products of BONTAC are widely used in fields such as nutritional health, biomedicine, medical beauty, daily chemicals and green agriculture. Disclaimer This article is based on the reference in the academic journal. The relevant information is provided for sharing and learning purposes only, and does not represent any medical advice purposes. If there is any infringement, please contact the author for deletion. The views expressed in this article do not represent the position of BONTAC. Under no circumstances will BONTAC be responsible for any claims, damages, losses, expenses or costs resulting directly or indirectly from your reliance on the information and material on this website.